Chicago Partners Investment Group LLC lifted its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 2.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,783 shares of the financial services provider’s stock after purchasing an additional 94 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in iShares Biotechnology ETF were worth $510,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Huntington National Bank boosted its stake in iShares Biotechnology ETF by 17.9% during the third quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock worth $153,000 after buying an additional 160 shares during the period. National Bank of Canada FI boosted its stake in iShares Biotechnology ETF by 5.9% during the third quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock worth $600,000 after buying an additional 229 shares during the period. Avior Wealth Management LLC boosted its stake in iShares Biotechnology ETF by 438.2% during the third quarter. Avior Wealth Management LLC now owns 3,229 shares of the financial services provider’s stock worth $470,000 after buying an additional 2,629 shares during the period. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in iShares Biotechnology ETF by 32.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock worth $96,533,000 after buying an additional 164,000 shares during the period. Finally, Main Management ETF Advisors LLC boosted its stake in iShares Biotechnology ETF by 2.5% during the third quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after buying an additional 14,535 shares during the period. 62.45% of the stock is owned by hedge funds and other institutional investors.
iShares Biotechnology ETF Stock Down 0.6 %
NASDAQ IBB opened at $137.85 on Tuesday. The company has a fifty day moving average of $136.33 and a two-hundred day moving average of $141.50. iShares Biotechnology ETF has a 52 week low of $123.60 and a 52 week high of $150.57.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Stories
- Five stocks we like better than iShares Biotechnology ETF
- What Investors Need to Know About Upcoming IPOs
- How to Invest in Small Cap Stocks
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- These Are the Dividend Stocks Insiders Bought in January
- 3 Warren Buffett Stocks to Buy Now
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.